Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study

A Single-Center, Open-Label, Single-Arm Exploratory Clinical Study on the Use of Autologous CAR-T Cell Therapy Injection for the Treatment of Refractory and Relapsing Ulcerative Colitis: A Preliminary Exploration of 12-Week Clinical Remission with Autologous CAR-T Cell Injection in Refractory and Relapsing Ulcerative Colitis.

NCT Number	NCT07435779
Lead Sponsor	Hebei Senlang Biotechnology Inc., Ltd.
Conditions	UC
Enrollment	12 participants
Start Date	2026-02-04
Primary Completion	2027-02-04 (estimated)
Study Completion	2028-02-04 (estimated)
Updated on ClinicalTrials.gov	2026-02-27